
The Longevity Revolution Is Coming — Will It Include You?
When most people think about longevity, they think about fitness trackers, sleep clinics, biohacking startups, or the latest personalized supplements. But as someone who has spent the past decade building a healthcare company in Bangladesh, I can tell you: the tools for living longer have been around a very long time. What's missing are the systems to make those tools available to everyone.
The evidence is clear: if everyone in the world had access to a basic health check once a year, we ... More could increase life expectancy by up to seven years across the globe.
The biggest breakthroughs in life expectancy won't come from flashy technology. They will come from preventing disease altogether — from ensuring that more people can detect and manage chronic illnesses before they become life-threatening.
Today, over 70% of deaths globally are caused by chronic, non-communicable diseases like heart disease, diabetes, and cancer. Modern longevity is about staying healthy, active, and free from chronic disease for as long as possible. As longevity expert Dr. Peter Attia has said, 'The goal isn't to avoid death entirely — that's impossible — but to delay the onset of the diseases that most commonly kill us.'
The goal isn't to avoid death entirely — that's impossible — but to delay the onset of the diseases that most commonly kill us.The evidence is clear: if everyone in the world had access to a basic health check once a year, we could increase life expectancy by up to seven years across the globe.
And yet, many people only seek care when they are already seriously ill. In emerging markets especially, the window for prevention closes too soon — often due to cost, distance, or a lack of trust in the system.
At Praava Health, we've seen how that can change. Through a combination of high-quality physical clinics and digital tools, we've served nearly a million patients in Bangladesh — and today, over 30% of our patients come to us for preventive care, not just treatment. Technology plays a critical role — not as a substitute for the doctor, but as a bridge that amplifies access and care. At Praava, digital tools allow us to reach underserved communities, automate clinical protocols, flag early signs of disease, and help patients take control of their health.
If we focus only on technology, we risk leaving vast populations behind. Nearly three billion people globally still lack internet access. Over a billion live without reliable electricity.
The good news is that we don't need fancy tech to improve healthspan. Even in the richest countries in the world, no technology tool or gadget can replace human connection, continuity, or care. No technology, no treatment, can substitute for the power of community. In fact, as more of us spend more and more time looking at screens rather than at each other, loneliness is one of the greatest and most underestimated health challenges of our time. We now know that social isolation doesn't just affect our mental wellbeing — it increases the risk of heart disease, dementia, and premature death as much as smoking or obesity.
Longevity begins with systems: trusted, accessible, affordable care.
Across the Global South, we've already seen how simple, system-level investments in prevention can dramatically improve outcomes:
These stories prove what's possible, even when resources are scarce. The tools to extend life are in frontline clinics, community health programs, and policies that make prevention accessible.
And the returns on longevity are not only social — they're economic. Longer, healthier lives translate into stronger labor markets, rising incomes, and growing consumer demand. In emerging markets, simple interventions can deliver outsized gains for both health and financial returns. Healthcare systems in Asia, for example, trade at 2-3x the valuations of comparable U.S. systems — driven by demand, demographic momentum, and the ability to leapfrog outdated, rigid infrastructure. These markets can build more efficient, tech-enabled health systems from the ground up.
Ultimately, each of us must be the quarterback of our own health and longevity. As Dr. Richa Chaturvedi, a leading endocrinologist in India, reminds us, 'Longevity is a fascinating mix of what we inherit from our parents and the choices we make every day. While our genes do set the stage—some people are simply born with a head start—most research agrees that how we live plays a bigger part in how long and how well we live. Things like what we eat, how active we are, how we handle stress, and whether we avoid harmful habits like smoking can make a huge difference, sometimes even outweighing family history. So, even if you don't come from a long line of centenarians, there's a lot you can do to stack the odds in your favour and enjoy a longer, healthier life.'
However, without systems that enable those choices, people — especially in the Global South — are left behind.
Longevity is a fascinating mix of what we inherit from our parents and the choices we make every day.The most effective healthcare systems are built on a foundation of prevention — not just flashy tech, but high-quality, accessible care that ensures everyone can benefit from something as simple and powerful as an annual health check.
To truly democratize longevity, we need:
✔ Affordable, high-quality healthcare and diagnostics, centered around primary care
✔ Financing tools like microinsurance and wellness-linked savings
✔ Investments in frontline workers and community health teams
✔ Regulations that promote access to nutritious food and clean environments
✔ Policies that remove barriers — particularly for women, rural communities, and aging populations
The same drivers fueling longevity businesses in the West — prevention, proactive care, system design — are even more scalable, and often more urgent, in the Global South.Building systems that empower healthier, longer lives isn't just a moral imperative — it's an economic one. And it's one of the most investable opportunities of our time.
If longevity is the next frontier of human progress, it must belong to all of us — not only those of us who can afford it.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
3 hours ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
3 hours ago
- Yahoo
Major update on plan to slash prescription medications to $25 for millions
The federal government will introduce legislation to parliament to cap the cost of Pharmaceutical Benefits Scheme (PBS) prescriptions to $25 this week. The cost-of-living move was one of Labor's major election promises and will save Aussies $200 million per year. Once passed, eligible medicines would be lowered from $31.60 to $25 from January 1 next year. Pensioners and concession cardholders will continue to pay just $7.70 for their prescriptions until at least 2030. Prime Minister Anthony Albanese said the cap was an example of cost-of-living relief that helped 'every Australian'. RELATED Major update on $5,520 HECS cash boost for millions to lift them out of debt Major warning after Aussie receives random $350 payment in her bank account Aussie 'appalled' by $4,000 ATO tax bill after common deductions rejected 'The size of your bank balance shouldn't determine the quality of your healthcare. My government will continue to deliver cost-of-living relief for all Australians,' he said. Health Minister Mark Butler said the move meant medicines would be their cheapest in decades. 'Cheaper medicines are good for the hip pocket and good for your health,' he said. 'For general patients, medicines haven't been this cheap since 2004." The change would lower the price of medicines by more than 20 per cent and follows an earlier round of price reductions in 2023. The government previously cut the maximum price of a PBS script from $42.50 to $30. The bill comes after US President Donald Trump flagged tariffs of up to 200 per cent on pharmaceuticals earlier this month. Pharmaceuticals are one of Australia's biggest exports to the US. According to the UN's Comtrade database, Australia exported $2.2 billion in products to the US last year. The Australian government has said it is not willing to trade away or do deals on the PBS. How will the cheaper medicines work? The PBS is the government subsidy program that allows Australians to get a wide range of prescription medicines at more affordable prices. There are two main prices for PBS medicines. The general rate is what applies to most people and is what would be lowered from $31.60 to $25. The concessional rate applies to concession-card holders and is currently frozen at $7.70 until 2030. There are more than 900 medicines on the PBS schedule, spread across more than 5,000 brands. You can check if your medication is on the PBS here.